Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by BioNTech SE

BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
Update on First BioNTainer for African-based mRNA Manufacturing Facility
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
BioNTech Expands Global Footprint by Acquiring GMP Manufacturing Site to Establish First mRNA Facility in Singapore
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
BioNTech to Report Third Quarter 2022 Financial Results and Operational Update on November 7, 2022
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
BioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
From BioNTech SE
Via Globe NewsWire
Tickers BNTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.